- Home
- MTA vs ORIC Comparison
MTA vs ORIC Comparison
Compare MTA & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTA | ORIC |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 685.0M | 783.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MTA | ORIC |
|---|---|---|
| Price | $8.10 | $8.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $7.50 | ★ $19.50 |
| AVG Volume (30 Days) | 531.7K | ★ 1.4M |
| Earning Date | 02-17-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,546,000.00 | N/A |
| Revenue This Year | $127.20 | N/A |
| Revenue Next Year | $75.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 108.91 | N/A |
| 52 Week Low | $2.52 | $3.90 |
| 52 Week High | $8.63 | $14.93 |
Technical Indicators
Market Signals| Indicator | MTA | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 57.81 | 27.93 |
| Support Level | $7.49 | $7.84 |
| Resistance Level | $8.30 | $8.33 |
| Average True Range (ATR) | 0.33 | 0.43 |
| MACD | -0.05 | 0.07 |
| Stochastic Oscillator | 53.07 | 18.04 |
Price Performance
Historical ComparisonAbout MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.